SecBot SecBot
6-K ·Filed Jun 29, 2026

GSK

GSK plc
NEUTRAL
Impact 3/10
Horizondays Processed4mo ago SEC0001654954-26-006269
Notable filing: 6-K
Actionable Insight • Neutral

The 0.05% trim by Dodge & Cox is a routine rebalancing move, not a conviction change. Monitor the next 13F filing for the full Q2 2026 position size. No immediate trading action warranted.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$52.81
T+0 close · Jun 29, 2026 · via day close
Latest settled
−3.96%
T+60 · $50.72
Vs SPY
−8.33%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 29 $52.81entry
  2. T+1 · 5mo ago −0.74%α −1.52% · $52.42
  3. T+5 · 4mo ago +0.53%α −0.86% · $53.09
  4. T+20 · 4mo ago −2.76%α −2.49% · $51.35
  5. T+60 · 8w ago −3.96%α −8.33% · $50.72
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dodge & Cox, a top-3 institutional holder of GSK, disclosed a reduction in its voting rights stake from 5.01% to 4.96%, crossing below the 5% UK notification threshold. The sale of approximately 2 million shares (based on the 0.05% decline) is a modest trim by a long-term value manager, not a material bearish signal for a $107B pharma company.

Key Facts

  • Dodge & Cox reduced its GSK voting rights stake from 5.01% to 4.96%, crossing below the 5% threshold on June 24, 2026.
  • Total voting rights held: 201,065,668 (4.96% of total), split between ordinary shares (88,816,040; 2.19%) and ADRs (112,249,628; 2.77%).
  • No financial instruments (options, swaps, etc.) were reported, the entire position is in common equity.
  • Dodge & Cox remains a top-3 institutional holder per the 13F snapshot ($3.2B position as of Q1 2026).

Financial Impact

Stake reduction of ~0.05% of total voting rights, representing roughly 2 million shares or ~$80-100M at current prices, a routine portfolio trim for a $3.2B position.

ownership_percentage

Risk Factors

  • Further selling by Dodge & Cox could signal reduced conviction, but the current 0.05% reduction is immaterial.
  • The 20-F annual report (filed 115 days ago) provides the broader financial context, no recent earnings or guidance updates are available in this filing.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
44% bullish (32 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-006269
Document: 0001654954-26-006269-index-headers.html0001654954-26-006269
Document: 0001654954-26-006269-index.html0001654954-26-006269
Document: 0001654954-26-006269.txt0001654954-26-006269

US Market Status

Market Closed · Opens Wed (10h 31m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 29, 2026